Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
144.6 USD | -1.90% | -1.68% | +9.78% |
07-09 | RBC Cuts Price Target on Neurocrine Biosciences to $136 From $141, Keeps Sector Perform Rating | MT |
07-03 | ANALYST RECOMMENDATIONS : Alphabet, Nike, Nvidia, Tesla, Starbucks... |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.78% | 14.56B | |
+20.03% | 126B | |
+23.61% | 117B | |
+22.77% | 27.52B | |
-18.07% | 20.87B | |
-14.01% | 17.01B | |
-14.81% | 16.26B | |
-46.10% | 15.09B | |
+52.34% | 13.89B | |
+143.76% | 12.18B |
- Stock Market
- Equities
- NBIX Stock
- News Neurocrine Biosciences, Inc.
- Transcript : Neurocrine Biosciences Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-11-2016 08